{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:05:02Z","timestamp":1787799902992,"version":"build-2784847793"},"reference-count":32,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A 64-year-old woman with hereditary hemorrhagic telangiectasia (HHT) characterized by a pathological variant in ACVRL1 presents to the clinic for follow-up. Manifestations of HHT include frequent epistaxis and gastrointestinal bleeding, leading to iron-deficiency anemia. Bevacizumab is initiated, with resolution of the anemia. While maintained on a regimen of bevacizumab every 6 weeks, she continues to report frequent epistaxis and has ongoing iron-deficiency requiring periodic iron infusions. She also finds the bevacizumab infusions inconvenient. She is interested in discussing other options for managing her disease.<\/jats:p>","DOI":"10.1182\/hematology.2024000675","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:06:45Z","timestamp":1733497605000},"page":"724-727","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Potential and emerging therapeutics for HHT"],"prefix":"10.1182","volume":"2024","author":[{"given":"Harish","family":"Eswaran","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj S.","family":"Kasthuri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2024121115410662200_hem2024000675C1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fgene.2015.00035","article-title":"Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia","volume":"6","author":"Ardelean","year":"2015","journal-title":"Front Genet"},{"issue":"12","key":"2024121115410662200_hem2024000675C2","first-page":"3166","article-title":"Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women","volume":"8","author":"Zhang","year":"2024"},{"issue":"2","key":"2024121115410662200_hem2024000675C3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI127425","article-title":"Correcting Smad1\/5\/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models","volume":"130","author":"Ruiz","year":"2020","journal-title":"J Clin Investig"},{"issue":"11","key":"2024121115410662200_hem2024000675C4","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1161\/STROKEAHA.115.010984","article-title":"Cerebrovascular manifestations of hereditary hemorrhagic telangiectasia","volume":"46","author":"Brinjikji","year":"2015","journal-title":"Stroke"},{"issue":"11","key":"2024121115410662200_hem2024000675C5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113571","article-title":"Potential Second- Hits in Hereditary Hemorrhagic Telangiectasia","volume":"9","author":"Bernabeu","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"2024121115410662200_hem2024000675C6","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1161\/01.CIR.0000058170.92267.00","article-title":"Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality","volume":"107","author":"Torsney","year":"2003","journal-title":"Circulation"},{"key":"2024121115410662200_hem2024000675C7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2015.00001","article-title":"Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era","volume":"6","author":"McDonald","year":"2015","journal-title":"Front Genet"},{"issue":"3","key":"2024121115410662200_hem2024000675C8","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ajhg.2013.07.004","article-title":"BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia","volume":"93","author":"Wooderchak-Donahue","year":"2013","journal-title":"Am J Hum Genet"},{"issue":"1","key":"2024121115410662200_hem2024000675C9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/hematology.2021000281","article-title":"Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management","volume":"2021","author":"Hammill","year":"2021","journal-title":"Hematology"},{"key":"2024121115410662200_hem2024000675C10","article-title":"Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia [published online 22 June 2017]","author":"Kasthuri","journal-title":"Am J Hematol"},{"issue":"1","key":"2024121115410662200_hem2024000675C11","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.chest.2021.07.2180","article-title":"A case of high-output heart failure","volume":"161","author":"Murray","year":"2022","journal-title":"CHEST"},{"issue":"10","key":"2024121115410662200_hem2024000675C12","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1007\/s00384-020-03670-3","article-title":"SMAD4 mutation and the combined juvenile polyposis and hereditary hemorrhage telangiectasia syndrome: a single center experience","volume":"35","author":"McDonald","year":"2020","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"2024121115410662200_hem2024000675C13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng1294-345","article-title":"Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1","volume":"8","author":"McAllister","year":"1994","journal-title":"Nat Genet"},{"issue":"2","key":"2024121115410662200_hem2024000675C14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/lt.21417","article-title":"Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia","volume":"14","author":"Mitchell","year":"2008","journal-title":"Liver Transpl"},{"issue":"1","key":"2024121115410662200_hem2024000675C15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10456-013-9383-4","article-title":"Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment","volume":"17","author":"Ardelean","year":"2014","journal-title":"Angiogenesis"},{"issue":"10","key":"2024121115410662200_hem2024000675C16","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood-2009-01-199166","article-title":"Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells","volume":"114","author":"Shao","year":"2009","journal-title":"Blood"},{"key":"2024121115410662200_hem2024000675C17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fgene.2015.00025","article-title":"Mouse models of hereditary hemorrhagic telangiectasia: recent advances and future challenges","volume":"6","author":"Tual-Chalot","year":"2015","journal-title":"Front Genet"},{"issue":"4","key":"2024121115410662200_hem2024000675C18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"issue":"6","key":"2024121115410662200_hem2024000675C19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/joim.13714","article-title":"Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial","volume":"294","author":"Dupuis-Girod","year":"2023","journal-title":"J Intern Med"},{"issue":"8","key":"2024121115410662200_hem2024000675C20","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"2024121115410662200_hem2024000675C21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"issue":"10","key":"2024121115410662200_hem2024000675C22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1017\/S0022215118001536","article-title":"The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review","volume":"132","author":"Harrison","year":"2018","journal-title":"J Laryngol Otol"},{"issue":"11","key":"2024121115410662200_hem2024000675C23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari","year":"2024","journal-title":"NEJM"},{"issue":"1","key":"2024121115410662200_hem2024000675C24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"issue":"51","key":"2024121115410662200_hem2024000675C25","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"issue":"23","key":"2024121115410662200_hem2024000675C26","doi-asserted-by":"crossref","first-page":"7410","DOI":"10.3390\/jcm12237410","article-title":"Tacrolimus as a promising drug for epistaxis and gastrointestinal bleeding in HHT","volume":"12","author":"\u00c1lvarez-Hern\u00e1ndez","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"2024121115410662200_hem2024000675C27","doi-asserted-by":"crossref","first-page":"e0228486","DOI":"10.1371\/journal.pone.0228486","article-title":"Bevacizumab for treating hereditary hemorrhagic telangiectasia patients with severe hepatic involvement or refractory anemia","volume":"15","author":"V\u00e1zquez","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"2024121115410662200_hem2024000675C28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J Intern Med"},{"issue":"11","key":"2024121115410662200_hem2024000675C29","doi-asserted-by":"crossref","first-page":"e0188943","DOI":"10.1371\/journal.pone.0188943","article-title":"Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients","volume":"12","author":"Guilhem","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"2024121115410662200_hem2024000675C30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia\u2013related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2024121115410662200_hem2024000675C31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"issue":"11","key":"2024121115410662200_hem2024000675C32","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/724\/2346852\/724eswaran.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/724\/2346852\/724eswaran.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:12:44Z","timestamp":1733947964000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/724\/526226\/Potential-and-emerging-therapeutics-for-HHT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000675","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}